Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud)

Emre, M; Leslie, G C; Muir, C; Part, N J; Pokorny, R; Roberts, R C
November 1994
Journal of Neurology, Neurosurgery & Psychiatry;Nov1994, Vol. 57 Issue 11, p1355
Academic Journal
journal article
No abstract available.


Related Articles

  • Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. Al-Ghazawi, Mutasim; Alzoubi, Mamoun; Faidi, Bashar // International Journal of Clinical Pharmacology & Therapeutics;Mar2013, Vol. 51 Issue 3, p255 

    Objectives: To assess the bioequivalence of two Tizanidine 4 mg tablet formulations (Tizanidine® of the Pharma International company, as test product, and Sirdalud® of Novartis as a reference product), and to investigate possible effects of smoking on pharmacokinetics of tizanidine....

  • Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique. Mirbagheri, Mehdi M.; Chen, David; Rymer, W. Zev // Journal of NeuroEngineering & Rehabilitation (JNER);2010, Vol. 7, p29 

    Background: Despite numerous investigations, the impact of tizanidine, an anti-spastic medication, on changes in reflex and muscle mechanical properties in spasticity remains unclear. This study was designed to help us understand the mechanisms of action of tizanidine on spasticity in spinal...

  • Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Backman, Janne T.; Granfors, Marika T.; Neuvonen, Pertti J. // European Journal of Clinical Pharmacology;Jun2006, Vol. 62 Issue 6, p451 

    Objective: Rifampicin greatly reduces the plasma concentrations of many drugs. Our aim was to characterise the inducibility of cytochrome P450 (CYP) 1A2 by rifampicin, using tizanidine and caffeine as probe drugs for presystemic and systemic CYP1A2-mediated metabolism. Methods: In a randomised,...

  • Pharmacokinetic Characterization of Tizanidine Nasal Spray, a Novel Intranasal Delivery Method for the Treatment of Skeletal Muscle Spasm. Vitale, Daniela Cristina; Piazza, Cateno; Sinagra, Tiziana; Urso, Vincenzo; Cardì, Francesco; Drago, Filippo; Salomone, Salvatore // Clinical Drug Investigation;Dec2013, Vol. 33 Issue 12, p885 

    Background and Objective: The skeletal muscle relaxant tizanidine is approved by the US FDA and the European Medicines Agency for treating spasticity and is supplied as tablets for oral administration. However, tizanidine has a poor bioavailability, due to extensive first-pass metabolism....

  • Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Backman, Janne T.; Schröder, Marika T.; Neuvonen, Pertti J. // European Journal of Clinical Pharmacology;Jan2008, Vol. 64 Issue 1, p17 

    We studied the effects of gender and smoking on the pharmacokinetics and effects of the cytochrome P450 (CYP) 1A2 substrate tizanidine. Seventy-one healthy young volunteers (male and female nonsmokers, male smokers) ingested 4 mg tizanidine. Plasma concentrations and pharmacodynamics of...

  • Design and Evaluation of Tizanidine Buccal Mucoadhesive Patches. Kulkarni, Gururaj S.; Babu, P. R. Sateesh // Journal of Applied Pharmaceutical Science;2012, Vol. 2 Issue 4, p74 

    Mucoadhesive buccal dosage forms are becoming more popular and patient acceptable dosage forms. By this route advantages are many as the dose can be reduced, avoidance of first pass metabolism and liver toxicity, etc. The Tizanidine has first pass metabolism because of this the patient has to...

  • Absorption of isophane (NPH) insulin and its clinical implications. Lauritzen, Torsten; Pramming, Stig; Gale, Edwin A.M.; Deckert, Torsten; Binder, Christian // British Medical Journal (Clinical Research Edition);7/17/1982, Vol. 285 Issue 6336, p159 

    Examines the absorption of isophane insulin in diabetics. Correlation between insulin absorption and plasma insulin and blood glucose concentrations; Manifestation of a slower absorption at higher doses; Rate of plasma elimination halftime of insulin.

  • tizanidine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1155 

    This article presents a nurse's guide to the antispasticity agent tizanidine. Tizanidine is indicated for the treatment of increased muscle tone associated with spasticity due to multiple sclerosis or spinal cord injury. Tizanidine works as an agonist at central alpha-adrenergic receptor sites....

  • Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p76 

    In this article, the author discusses the clinical efficacy and safety of sublingual tizanidine in multiple sclerosis. It notes that tizanidine ameliorates spasticity via its effect as a central adrenergic agonist due to its short plasma half-life. It recommends that one must consider shifting...

  • TIZANIDINE.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p800 

    The article presents information on tizanidine, an antispastic drug and muscle relaxant, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.


Read the Article


Sign out of this library

Other Topics